home / stock / casi / casi news

CASI News and Press, CASI Pharmaceuticals Inc.

Stock Information
Company Name: CASI Pharmaceuticals Inc.
Stock Symbol: CASI
Market: OTC
Website: casipharmaceuticals.com
Menu
Get CASI Alerts

News, Short Squeeze, Breakout and More Instantly...
CASI - US Companies Moving the Markets, Morning edition
Thu, Feb 26, 2026 as of 10.00 am ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.2% to $1.59 on volume of 363,266,929 shares XWELL Inc. (XWEL) rose 220.1% to $1.21 on volume of 352,958,775 shares Classover Holdings Inc. (KIDZ) rose 13.4% to $0.1085 on volume ...
CASI - US Companies Moving the Markets, Evening edition
Wed, Feb 25, 2026 as of 4:00 pm ET

A look at the top 10 most actives in the United States XWELL Inc. (XWEL) rose 222.8% to $1.22 on volume of 330,501,169 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.8% to $1.58 on volume of 298,228,172 shares Classover Holdings Inc. (KIDZ) rose 14.4% to $0.1095 on volume ...

CASI - CASI Pharmaceuticals to be delisted from Nasdaq, shares to move to OTC Market

2026-02-25 09:08:24 ET More on CASI Pharmaceuticals CASI Pharmaceuticals wins Nasdaq extension to meet listing rules Seeking Alpha’s Quant Rating on CASI Pharmaceuticals Historical earnings data for CASI Pharmaceuticals Financial information for CASI P...

CASI - CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmu...
CASI - CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously approved by FDA for Phase 1 AMR study SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS N...

CASI - CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

Additional proof of concept data consistent and strengthen data set shared at ASH 2025 Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clin...

CASI - CASI Pharmaceuticals wins Nasdaq extension to meet listing rules

2025-12-23 16:12:21 ET More on CASI Pharmaceuticals CASI Pharmaceuticals appeals NASDAQ delisting determination Seeking Alpha’s Quant Rating on CASI Pharmaceuticals Historical earnings data for CASI Pharmaceuticals Financial information for CASI Pharma...
CASI - CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and ...

CASI - CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the "Company"), a clinical-stage biopharmaceutical company developing CID-103, ...

CASI - CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmun...
Next 10